Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tepotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 19/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tepotinib SCHEMBL29379106 | 1.00 | MET (1.00) | METNQO2 | |
| Tepotinib SCHEMBL1296467 | 0.99 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL30259391 | 0.99 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL29550043 | 0.99 | MET (0.98) | METNQO2 | |
| Tepotinib SCHEMBL1295616 | 0.99 | MET (0.98) | METNQO2 | |
| SCHEMBL24713684 | 0.93 | MET (0.87) | METNQO2 | |
| SCHEMBL2462861 | 0.92 | MET (0.85) | METNQO2 | |
| SCHEMBL2530219 | 0.92 | MET (0.84) | METNQO2 | |
| SCHEMBL2514982 | 0.92 | MET (0.84) | METNQO2 | |
| Hydrochloric Acid SCHEMBL17823301 | 0.92 | MET (0.84) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137681-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | US | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087699-A1 | NEW TREATMENT OF NON-SMALL CELL LUNG CANCER | PIERRE FABRE MEDICAMENT (FR) | 2026-04-30 | — | — | WO | claimed |
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| US-12605395-B2 | Materials and methods for immunosuppressive tumor microenvironment-targeted cancer therapy | UNIVERSITY OF CINCINNATI (US) | 2026-04-21 | — | — | US | claimed |
| US-20260041653-A1 | AN HDAC INHIBITOR FOR TREATING CANCER WITH A MODIFIED STK11 ACTIVITY OR EXPRESSION | TANGO THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | claimed |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | JOINT BIOSCIENCES SH LTD (CN) | 2026-01-22 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| WO-2013139423-A1 | COMBINATION OF A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE HAVING ANTI-CANCER ACTIVITY WITH OTHER ANTI-TUMOR COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | WO | claimed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| US-8329692-B2 | Pyrimidinyl pyridazinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-11 | — | — | US | claimed |
| US-20120295908-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-11-22 | — | — | US | claimed |
| EP-2164844-B1 | PYRIMIDINYL PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2012-06-27 | — | — | EP | claimed |
| US-20110269767-A1 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-03 | — | — | US | claimed |
| EP-2373640-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | Merck Patent GmbH (DE) | 2011-10-12 | — | — | EP | claimed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| US-20100197690-A1 | Pyrimidinyl Pyridazinone Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2010-08-05 | — | — | US | claimed |
| WO-2010078897-A1 | NOVEL POLYMORPHIC FORMS OF 3-(1-{3-[5-(1-METHYL-PIPERIDIN-4YLMETHOXY)-PYRIMIDIN-2-YL]-BENZYL}-6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041653-A1 | AN HDAC INHIBITOR FOR TREATING CANCER WITH A MODIFIED STK11 ACTIVITY OR EXPRESSION | HDAC9, HDAC11, HDAC4 | MET 1507/4885NQO2 3269/4885 |
| US-20110269767-A1 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof | BRCA1, MAPK4, MAPK1 | MET 1452/4885NQO2 2900/4885 |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | SGMS2, SGMS1, LIPA | MET 1451/4885NQO2 4875/4885 |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 562/4885 |
| US-12605395-B2 | Materials and methods for immunosuppressive tumor microenvironment-targeted cancer therapy | TLR2, MYD88, TLR6 | MET 582/4885NQO2 4361/4885 |
| US-20260137681-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | MET 1/4885NQO2 3935/4885 |
| US-20120295908-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATIVES | MET, MERTK, ABL1 | MET 1/4885NQO2 1075/4885 |
| US-20260021149-A1 | METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG | ERBB2, BTK, ERBB3 | MET 6/4885NQO2 2639/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885NQO2 541/4885 |
| US-20100197690-A1 | Pyrimidinyl Pyridazinone Derivatives | MET, MERTK, ABL1 | MET 1/4885NQO2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.